All In Biotech

Drug Trial Radar · NCT07929844

Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual Onychomycosis

A Phase 2, Multicenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of SKX-16 (Luliconazole 10% Solution) in Participants With Mild to Moderate Distal Subungual Onychomycosis of the Toenails

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Nov 24, 2026

Primary completion

Sep 23, 2028

Study completion Oct 21, 2028

Sponsor

Lead sponsor
SATO Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel group, double blind, vehicle-controlled study in which SKX-16 or vehicle (2:1 randomization) is applied once a day for 52 weeks to all affected toenails to participants with mild to moderate distal subungual onychomycosis (DSO) of the toenails involving between 20 to 50% of at least one great toenail at Screening.

Conditions

  • Onychomycosis of Toenails

Interventions

  • SKX-16 (Luliconazole 10% Solution)Drug

    Applied topically once daily for 52 weeks to all affected toenails identified by the investigator, followed by a Week 56 follow-up visit.

  • Vehicle solutionDrug

    Applied topically once daily for 52 weeks to all affected toenails identified by the investigator, followed by a Week 56 follow-up visit, under the same conditions as the active arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Cure at Week 56Time frame: 56 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • SKX16B01 Clinical Study - Site 105

    Los Angeles, California

  • SKX16B01 Clinical Study - Site 101

    San Francisco, California

  • SKX16B01 Clinical Study - Site 104

    Miami, Florida

  • SKX16B01 Clinical Study - Site 109

    Miami, Florida

  • SKX16B01 Clinical Study - Site 111

    College Station, Texas

  • SKX16B01 Clinical Study - Site 119

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.